Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


South Korea Discusses Opening State-owned Pharma For Stable Drug Supply

This article was originally published in PharmAsia News

Executive Summary

The president of the National Health Insurance Service told lawmakers his agency is assessing the feasibility of a state-owned pharma, which the domestic industry group said could put a pinch on reimbursement negotiations.

You may also be interested in...

Thailand's Cost Control Measures And What They Mean For Pharma - IMS Analysis

SHANGHAI - Thailand's recent clampdown on public healthcare spending means multinational drug makers will have to look for news ways to tap the country's drug market, according to IMS Health

Korea FDA Rebuts Reports Of Compulsory Licensing For Roche's Tamiflu

SEOUL - Korea FDA rejected Friday local press reports that the Korean government - jittery over the rising number of local people infected with A/H1N1- will soon exercise the option of "compulsory licensing" to produce generic versions of Roche's Tamiflu (oseltamivir)

Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III

Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts